7/10/2013

Servier granted Amgen rights to market its heart failure and angina drug Procoralan, or ivabradine, in the U.S. as well as an exclusive option to develop and market its experimental heart failure drug S38844. Servier could get $50 million upfront plus milestone fees and sales royalties for ivabradine, which is already cleared in Europe. The deal also gives Servier rights to commercialize Amgen's heart failure drug candidate omecamtiv mecarbil in Europe.

Related Summaries